Covira Revenue and Competitors
Estimated Revenue & Valuation
- Covira's estimated annual revenue is currently $2M per year.
- Covira's estimated revenue per employee is $155,000
Employee Data
- Covira has 13 Employees.
- Covira grew their employee count by -13% last year.
Covira's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Assistant | Reveal Email/Phone |
Covira Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Covira?
Covira Surgical is a biopharmaceutical company focusing on novel therapeutic alternative to infection control that is distinct from traditional antibacterial approaches. Covira has developed a platform technology called Pi-PEG that suppresses bacterial virulence without impacting its normal growth. Pi-PEG is the discovery from Dr. John Alverdy’s lab, a leading microbiome scientist and world leader in GI surgical infection. Covira aims to revolutionize infection prevention by developing and applying agents into the gut that seek to collaborate with, rather than eliminate key members of the microbiome.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.1M | 13 | N/A | N/A |
#2 | $0.4M | 13 | -13% | $42.9M |
#3 | $1M | 13 | -24% | $183.3M |
#4 | $3.5M | 13 | -7% | $1.9M |
#5 | $35M | 13 | 0% | N/A |